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Mass spectrometryEicosanoids are oxidation products of C20 polyunsaturated fatty acids (e.g. arachidonic acid) that include
prostaglandins, thromboxanes, leukotrienes and hydroperoxy fatty acids. They have important biological
roles in vivo, including regulation of renal, cardiovascular and gastrointestinal function. Historically, eicosanoids
were thought tomediate their signaling actions exclusively as free acids, however evidence is now emerging that
they may also be generated attached to other functional groups including phospholipids and glycerol, and that
these more complex forms are pathophysiological signaling mediators in their own right. Early studies showed
that exogenously added eicosanoids could become esteriﬁed into membrane phospholipids of cells, while more
recently, itwas uncovered that esteriﬁed eicosanoids are formedendogenously. This review summarizes our cur-
rent knowledge of this area, starting with the early discoveries documenting what is known about eicosanoid
generation and their esteriﬁcation, andmoving on to discuss the discovery that esteriﬁed eicosanoids are gener-
ated endogenously by a number of different cell types. Recent research that is highlighting new structures and
functions of these important lipid mediators will be presented. This article is part of a Special Issue entitled: Ox-
idized phospholipids—their properties and interactions with proteins.
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Eicosanoids are oxidation products of C20 polyunsaturated fatty
acids (e.g. arachidonic acid) that include prostaglandins, thrombox-
anes, leukotrienes and hydroperoxy fatty acids. They have important
biological roles in vivo, including regulation of renal, cardiovascular
and gastrointestinal function. Historically, eicosanoids were thought
to mediate their signaling actions exclusively as free acids, however
evidence is now emerging that they may also be attached to other
functional groups including phospholipids and glycerol, and that
these more complex forms may also be pathophysiological signaling
mediators in their own right. Early studies showed that exogenously
added eicosanoids could become esteriﬁed into membrane phospho-
lipids of cells, while more recently, it was uncovered that such
esteriﬁed eicosanoids were formed endogenously. This review sum-
marizes our current knowledge of this area, starting with the early
discoveries documenting what is known about eicosanoid generation
and their esteriﬁcation, and moving on to discuss the discovery that
esteriﬁed eicosanoids are generated endogenously by a number of
different cell types. These discussions will include recent research
that is highlighting new structures and functions of these important
lipid mediators.2. Generation of free eicosanoids
Eicosanoids are generated by three separate enzyme families,
lipoxygenases (LOX), cyclooxygenases (COX) and cytochrome P450
(CYP), which catalyze lipid peroxidation in a stereo- and regio-
speciﬁc manner (Fig. 1). All display strict cell and tissue expression
patterns, and their activities are controlled by both transcriptional
and post-transcriptional regulation. In terms of esteriﬁed eicosanoids,Arachidonic 
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Fig. 1. Summary of eicosanoid generating pathall three enzyme families have been characterized in vitro and in vivo
as sources.2.1. Lipoxygenases
Lipoxygenases catalyze the stereo selective oxygenation of poly-
unsaturated fatty acids containing at least one (1Z,4Z)-penta-1,4-die-
noic system to the corresponding hydroperoxy derivatives. The
radical mechanism of lipoxygenase occurs in three steps, (i) hydrogen
abstraction, the position of which depends on the active site of the
LOX isoform, (ii) radical rearrangement and (iii) oxygen insertion.
LOXs are classiﬁed based on their position of oxygen insertion in
the arachidonate substrate. LOXs have been characterized in human
and mouse platelets, which express the platelet 12-LOX isoform,
humanmonocytes (15-LOX), human neutrophils (5-LOX) andmurine
peritoneal macrophages (12/15-LOX). There are also a number of skin
isoforms, including 12R-LOX and 8-LOXs. The primary product of LOX
oxidation is the unstable hydroperoxide, which is rapidly reduced to
its corresponding hydroxide in a reaction catalyzed by glutathione
peroxidases (GPX). For example, in the case of platelet 12-LOX, the
hydroperoxide, 12S-hydroperoxyeicosatetraenoic acid (12S-HpETE),
is reduced to 12-hydroxyeicosatetraenoic acid (12S-HETE). Alterna-
tively, further LOX metabolism of the hydroperoxides forms lipoxins
(e.g. LXA4) and hepoxilins. Since LXA4 generation requires the action
of 15- and 5-LOX, or 5- and 12-LOX, it is believed that their formation
requires sequential transcellular metabolism. HETEs can also be
oxidized to form their keto derivatives, ketoeicosatetraenoic acid
(KETEs), usually via the action of either 5-hydroxyeicosanoid dehy-
drogenase (HEDH) or 15-prostaglandin dehydrogenase (PGDH). For
a detailed review of LOX enzymes and their products, the reader is di-
rected to [1–5].Acid
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Table 1
Summary of esteriﬁed eicosanoids generated by mammalian cells, and their actions,
where known.
Cell type Species generated Function
Exogenous
Epithelial cells 16-, 17-, 18-, 19-, 20-HETE-
PE/PS/PI/PC
15-HETE-PI/PE
12-HETE-PI/PE/PC/PS
5-HETE-PE/PC
Endothelial cells 5-HETE-PC Inhibits histamine- and
arachidonate-stimulated
production of PGE2 and 6-
ketoPGF1α in human en-
dothelial cells.
12-HETE-PC
15-HETE-PI
16-, 17-, 18-, 19-, 20-HETE-
PE/PS/PI/PC
Neutrophils 15-HETE-PC/PI
Murine
macrophages
15-HETE-PC/PI
Human
peripheral blood
mononuclear cells
12-HETE-PI
Endogenous
Platelets 12-HETE-PE/PC Enhances coagulation of
platelets.
Murine
macrophages
12-HETE-PE Calcium mobilization and
activation of the ERK/MAPK
pathway. Inhibits LPS/IFNγ-
induced IL-12 and IL-23
expression in microglia and
macrophages by reducing
expression of IL-12p40.
PGE2-G
2-AG
PGH2-G, which is then
converted to PGD2-G, PGE2-D,
PGF2α-G and PGI2-G
PGE2-AEA
Human peripheral
blood monocytes
15-HETE-PE Inhibition of LPS-induced G-
CSF and TNFα generation by
human monocytes. Inhibi-
tion of NET formation by
neutrophils. Promotes
MUC5AC formation.
Neutrophils 5-HETE-PE/PC Inhibition of NET formation.
Enhances IL-8 and super-
oxide generation by
neutrophils.
Leprosy lesions,
low density
lipoproteins
PC-esteriﬁed isoprostanes Exacerbate leprosy infection.
IncreaseMCP-1, IL-8 genera-
tion via PPAR-α in endothe-
lial cells, increase monocyte
binding to endothelium.
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Cyclooxygenases, also known as prostaglandin endoperoxide H
synthases, catalyze the conversion of arachidonic acid and oxygen
to prostaglandin H2 (PGH2). The mechanism includes a cyclooxygen-
ase reaction in which arachidonate is converted to prostaglandin G2
(PGG2), and a peroxidase reaction in which PGG2 undergoes a two-
electron reduction to PGH2. It is initiated by oxidation of the heme
peroxidase to anoxoferryl porphyrin cation radical, which then oxidizes
a tyrosine to a tyrosyl radical. This mediates hydrogen abstraction from
arachidonate to yield an arachidonyl radical and is followed
by rearrangements and sequential additions of oxygen at C-11 and C-
15 to yield PGG2. Finally, the peroxidase activity reduces the 15-
hyroperoxide group of PGG2 to its corresponding alcohol yielding
PGH2. There are two isoforms of COX. COX-1, which is constitutively
expressed by platelets and the gastrointestinal tract and is of particular
importance for gastrointestinal function. COX-2 is the inducible form of
the enzyme, the expression of which is enhanced by various cytokines
and growth factors [6,7]. Primary products of COX often undergo further
enzymatic metabolism to form secondary eicosanoids and their metab-
olites such as prostaglandin E2 (PGE2), D2 and thromboxaneA2 (TXA2).
These possess potent biological activities at nM concentrations, includ-
ing regulating inﬂammation, pain and thrombosis.
2.3. Cytochrome P450
Cytochrome P450s comprise a family of membrane bound heme-
proteins that catalyze the redox-coupled activation ofmolecular oxygen
and the delivery of an active form of atomic oxygen to a ground state
substrate carbon acceptor. These enzymes are widely distributed in
plants, insects, and animal tissues. P450s behave as classic monooxy-
genases with the enzymatic cleavage of molecular oxygen directly
followed by the insertion of a single atom of oxygen into the substrate,
while the remainder is released as water. Catalytic turnover requires
electron transfer from NADPH to the P450 heme iron, a reaction cata-
lyzed by a membrane bound ﬂavoprotein, NADPH-cytochrome P450
reductase [8–10]. Eicosanoid products of this pathway include epoxy-
lipids (EETs) and omega hydroxylated fatty acids, such as 20-HETE.
3. Generation of esteriﬁed eicosanoids by incorporation of
exogenous HETEs into cellular lipids
Until recently, it was widely believed that most eicosanoids are
both generated and then signal as free carboxylic acids. Speciﬁcally,
arachidonate is hydrolyzed from membrane phospholipids (PL) by
phospholipases, in particular cytosolic PLA2, which acts on primarily
phosphatidylcholine (PC). Following this, eicosanoids diffuse out of
the cell and activate G-protein coupled receptors on neighboring
cells to trigger tightly regulated signaling events. In contrast to this,
a number of groups in the 1980s–90s showed that primary and cul-
tured cells could take up radio-labeled HETEs and incorporate them
into several classes of phospholipids. The phenomenon was reported
in a variety of cell types and using several different HETE positional
isomers. This is discussed below and summarized in Table 1.
3.1. Epithelial cells
In kidney epithelial cells, exogenous 5-HETEwas shown to be incor-
porated primarily into PC and PE, within both microsomal and plasma
membranes [11]. 12-HETE was incorporated into PE, PC, PS and PI of
the same cell line, and into PC and PE of human bronchial epithelial
cells [11,12]. In contrast, 15-HETE was incorporated primarily into PI
in a lung epithelial cell line and also kidney epithelial cells [13,14]. Final-
ly a study in tracheal epithelial cells showed 15-HETE being incorporat-
ed into PI, while 5- and 12-HETEwere incorporated into PC and PE [15].
Overall, epithelial cell studies show that exogenous 5- and 12-HETEs areincorporated mainly into the most abundant phospholipids of these
cells (e.g. PE and PC), however uptake of 15-HETE into the far less abun-
dant PI appears to be more selective. Mechanisms of HETE incorpora-
tion have not been characterized but are likely to involve fatty acyl
CoA ligases, such as members of the MBOAT or LPCAT families that
esterify free fatty acids into phospholipids. However, their potential
roles in HETE esteriﬁcation have not yet been studied. Selective incor-
poration of 15-HETE into different phospholipids as opposed to 5- or
12-HETE indicates that distinct pathways may exist for esteriﬁcation
of different eicosanoid positional isomers.
3.2. Endothelial and kidney cells
Similar studies were performed in aortic endothelial cells, with
12-HETE incorporated into PC within microsomal membranes, 15-
HETE into PI, and 20-HETE into various phospholipids of aortic endo-
thelial cells [16–18]. Separate studies showed that 5-HETE is incorpo-
rated into PC in human endothelium [19]. In kidney cells, 5-HETE is
incorporated into di- and mono-glycerides of adrenal glomerulosa
cells, and 12-HETE is incorporated into PC, while cortex and medulla
tissues of the kidney also contain esteriﬁed cytochrome P450-derived
HETEs (16-, 17-, 18-, 19-, 20-HETE) [20,21]. As for epithelial cells, 15-
HETE is again preferentially incorporated into PI but the mechanistic
basis for this is unknown.
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Several studies showed that exogenous HETEs could be incorporat-
ed into phospholipids of various immune cells. Brezinski and Serhan
demonstrated 15-HETE uptake by neutrophils and incorporation into
PI (20%) while another 4% was incorporated into other PL classes in-
cluding PE and PC. In contrast, 5-HETEwas predominantly incorporated
into PC or triglycerides [22]. Similarly, 15-HETE has been shown to be
taken up by murine resident macrophages and incorporated into PI,
PC and PE phospholipids [23]. Finally 12-HETE is esteriﬁed into PC and
PI phospholipids in human peripheral blood mononuclear cells, and
this incorporation remains stable with 50% of the HETE-PL pool still
present after 18 h [24]. In all these studies, incorporation of free
HETEs takes place over long periods of several hours. A role for esteri-
ﬁed HETEs acting as a pool of “stored” eicosanoid which can be released
on further agonist activation was proposed, and in support, fMLP, phor-
bol or calcium ionophore (A23187) was shown to mediate deacylation
of PI and release of 15-HETEwhich subsequently acts as a second signal
to inhibit LTB4 generation by the neutrophils themselves [22].
While these studies concentrated on the fate of exogenously added
HETEs, the incorporation of endogenously generated eicosanoids was
not explored. Importantly, in many experiments, HETE positional
isomers were added that would not be expected to be generated by
the cells themselves, and at variable concentrations. For example, neu-
trophils generate 5- but not 12- or 15-HETEs while endothelial cells do
not generally express LOX isoforms under basal conditions. Thus, these
experiments deﬁned patterns of HETE incorporation that might be
expected to require transcellular HETEmovement during inﬂammation
or cell activation.Whether such HETE incorporation into phospholipids
occurs in vivo is not known.
4. Acute generation of esteriﬁed eicosanoids using
endogenous substrate
While previous studies demonstrated incorporation of exogenous
HETEs into cellular complex lipids, the speciﬁc molecular species of PL
involved were not deﬁned. More recently, the development of new
generation high sensitivity bench top mass spectrometers has enabled
identiﬁcation of speciﬁc molecular species of esteriﬁed eicosanoids
present in complex biological samples. Speciﬁcally, it has allowed iden-
tiﬁcation of the fatty acid composition of these lipids without extensive
puriﬁcation or derivatization. The most widely used method for the
detection of free and esteriﬁed eicosanoids is electrospray ionization
(ESI) combined with reverse phase liquid chromatography (RP-HPLC)
tandem mass spectrometry (MS/MS). Phospholipids and eicosanoids
ionize readily using ESI and are separated well based on their fatty
acid composition using RP-HPLC. Once ionized, parent ions can be frag-
mented on collision induced dissociation (CID) giving characteristic
daughter ions that can identify either esteriﬁed or free fatty acid eicos-
anoids. These methods are described in detail in several reviews
[25–27]. Although this has not yet been applied to the study of the
fate of exogenously-added HETEs, it has been used to uncover several
new families of bioactive esteriﬁed eicosanoids, including esteriﬁed iso-
prostanes, isofurans and isolevuglandins, and speciﬁc LOX-derived es-
teriﬁed HETEs, that are generated acutely by activated human and
murine platelets, neutrophils and monocytes/macrophages [28–33].
These will be described in detail in the following sections and are sum-
marized in Table 1.
4.1. Monocytes and macrophages
4.1.1. Esteriﬁed LOX products
12/15-LOX is expressed in monocytes/macrophages in response to
interleukin-4 and -13 and oxidizes arachidonate at either C12
(mouse, rat, pig) or C15 (human, rabbit) [34,35]. The human isoform
is referred to as 15-LOX or 15-LOX1. In 2005, we reported that humanmonocytes induced with IL-4 acutely generate a family of four ester-
iﬁed 15-HETEs following activation with ionophore (A23187). These
comprise one diacyl and three plasmalogen PE species (i.e. 18:0a,
18:0p, 18:1p, 16:0p/15-HETE-PE) [32] (Fig. 2). Similarly, murine peri-
toneal macrophages generate the equivalent 12-HETE-PEs, since they
express the functional equivalent, 12/15 LOX [31]. In both cases,
HETE-PEs appear within 5 min of activation, and levels remain fairly
stable over time, up to 3 h. To date the only known agonist to stimu-
late the generation of these lipids is ionophore (A23187), which pro-
motes calcium mobilization and subsequent translocation of the
enzyme to the inner membrane surface. Various physiological activa-
tors have been tested, including LPS, zymosan, β-glucan, ﬂagellin,
PAM3CSK4 and a cell free supernatant derived from a clinical isolate
of Staphylococcus epidermidis, but all were inactive. Monocytes and
macrophages already contain basal levels of HETE-PEs that generally
increase only 2–3-fold on ionophore (A23187) activation [31,32].
This suggests that the enzyme may be already constitutively active,
generating HETE-PEs without inﬂammatory stimulation and that the
lipids are performing homeostatic functions. This is different to
other LOXs (e.g. 5-LOX and platelet 12-LOX) that are inactive in rest-
ing cells and switched on by pathophysiological agonists (see later).
Unique among LOX isoforms, the 15-LOX can directly oxidize es-
teriﬁed arachidonate in phospholipids [36]. This has been shown
both using puriﬁed rabbit 15-LOX and also in human eosinophils
activated with ionophore (A23187). Oxidation of membranes by 15-
LOX is mediated by a combination of hydrophobic interactions be-
tween surface-exposed hydrophobic amino acid side chains and
membrane lipids, and calcium, which forms salt bridges between
the negatively charged head groups of the phospholipids, and the
acidic surface amino acids of the membrane contact plane of the en-
zyme thereby supporting the whole complex [37]. Thus, in intact
cells, this LOX isoform could potentially generate esteriﬁed HETEs ei-
ther through direct oxidation of phospholipids, or through oxidation
of free arachidonate, which would then be re-esteriﬁed (Fig. 3). In
monocytes/macrophages, using stable isotope techniques, we found
that HETE-PEs are generated by direct attack on membrane phospho-
lipids by the enzyme, with no requirement for hydrolysis of arachido-
nate by phospholipases [31,32]. It is unknown however, whether
lipoxygenases show any speciﬁcity for particular phospholipid sub-
strates in terms of their head group.
In addition to HETE-PEs, human IL-4 stimulated monocytes and
murine peritoneal macrophages generate analogous hydroperoxyei-
cosatetraenoic acid-PEs (HpETE-PEs) and ketoeicosatetraenoic acid-
PEs (KETE-PEs), with positional isomers matching cellular LOX iso-
form expression, and the same molecular species of PE as for HETE-
PEs. In general, amounts of these are lower than for HETE-PEs, but
their generation is also stimulated by ionophore (A23187) and the
lipids are absent in macrophages from 12/15-LOX−/− mice (Ham-
mond et al., unpublished). It is believed that HpETE-PEs are generated
by LOX, and then reduced to HETE-PEs by cellular glutathione perox-
idases. Approximately 50% of the HpETE-PE is reduced to HETE-PE in
monocytes and macrophages, with the rest decomposing over 3 h fol-
lowing its generation to unknown lipid products (Hammond et al.,
unpublished).
As well as in vitro generation, 12/15-LOX-derived HETE-PEs have
also been reported in vivo. In mice, 12-HETE-PEs are found in the
peritoneal cavity, peritoneal membrane, lymph nodes, and intestines,
similar to the distribution of 12/15-LOX derived free 12-HETE. In the
peritoneal cavity, 12-HETE-PEs are associated with the resident peri-
toneal macrophage population present in the cavity of naïve animals.
Following the induction of peritonitis (Toll receptor dependent) by
either live bacteria or bacterial products, 12-HETE-PEs and 12/15-
LOX expressing cells are rapidly cleared, and then reappear during in-
ﬂammatory resolution. This further supports the idea that HETE-PEs
play a role in immune regulation and/or inﬂammation resolution
[31,38]. In contrast, levels of 12-HETE-PEs were elevated in a Th2
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Fig. 2. Structures of HETE-PEs generated by ionophore (A23187)-activated IL-4-treated human monocytes.
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ciding with the peak of IL-4 and IL-13 generation [31]. This observa-
tion is consistent with the ability of Th2 cytokines to strongly
induce the enzyme. Thus, 12/15-LOX-derived HETE-PEs could be as-
sociated with eosinophils or lung macrophages that are recruited
and differentiate during airway inﬂammation. The human analogs,
15-HETE-PEs, are also detected in cultured human bronchial airway
epithelia and their generation can be stimulated in culture using IL-
4 [39].PLA2
12-LOX
5-LOX
FACL?
12/15-LOX
A
B
Fig. 3. Two potential mechanisms exist to explain acute generation of HETE-PLs by LOX
oxidation. Structures in pink represent oxidized fatty acid chains. Panel A. Hydrolysis-
dependent formation. PLA2 hydrolysis followed by 12-LOX oxidation, then re-
esteriﬁcation using fatty acid CoA ligase (FACL), e.g. in neutrophils and platelets.
Panel B. Direct membrane oxidation. Direct oxidation of membrane PL by 12/15-LOX,
e.g. monocytes/macrophages.4.1.2. Esteriﬁed COX products
Zymosan-activated peritoneal macrophages and murine macro-
phage cell lines generate esteriﬁed eicosanoids via the action of COX.
Naïve peritoneal cells express mainly COX-1 and little COX-2, however
the latter is strongly induced using microbial products including zymo-
san and LPS. Marnett and co-workers have conducted several elegant
studies that show generation of esteriﬁed COX products in these cells,
in response to inﬂammatory activation. Speciﬁcally, COX-2 can oxidize
endocannabinoid substrates 2-arachidonylglycerol (2-AG) or arachido-
nyl ethanolamine (AEA) to form novel lipids, for example, prostaglan-
din H2 glycerol ester (PGH2-G), which is then converted to PGD2-G,
PGE2-D, PGF2α-G and PGI2-G, by additional enzymes [40,41]. Due to
the lack of a side pocket near the base of the active site, COX-1 is only
weakly able to oxidize 2-AG and is not thought to be a signiﬁcant source
of these lipids. COX-2 exhibits comparable kcat/Km for 2-AG as AA, and
both 2-AG and AEA are present at appreciable concentrations in mam-
malian tissues. The pattern of esteriﬁed prostaglandins generated
from endogenous 2-AG oxidation by COX-2 matches that of free eicos-
anoids, although these are present at 500–1000 fold lower concentra-
tions than their free acid forms [42]. Generation of PGD2-G is calcium
dependent and thought to be mediated by sequential action of diacyl-
glycerol (DAG) lipase (hydrolysis of DAG to 2-AG), followed by COX-2
[43]. Related to this, metabolism of 2-AG has also been shown by 15-
LOX (human), both in vitro and in cells to form 15-HETE-G, a PPARγ
ligand [44].
4.2. Platelets
Platelets express a platelet-speciﬁc 12-LOX isoform, and their ability
to release high levels of free eicosanoids such as 12-HETE (40–60 ng/
4×107 platelets) on agonist activation (thrombin, collagen) has long
been known. The function of this isoform is unclear however since 12-
HETE is relatively inactive in terms of regulating platelet function di-
rectly. We recently found that human platelets generate four PE
and two PC-esteriﬁed 12-HETEs including both plasmalogen and
acyl forms (5.85±1.42 (PE) and 18.35±4.61 (PC) ng/4×107 cells).
The six molecular species of esteriﬁed HETEs generated by human
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18:0p, 18:1p, and 16:0p/12-HETE-PE and 18:0a and 16:0a/12-HETE-
PC. Their generation is stimulated by either collagen, thrombin, convul-
xin or ionophore (A23187) within 5 min, and they continue to elevate
up to 3 h post activation [29,32]. In response to thrombin, they are
formed via activation of PAR-1/4 receptors, utilizing several intracellu-
lar signaling intermediates including Ca2+, protein kinase C, sPLA2,
and src tyrosine kinases. Using PLA2 inhibitors and stable isotope incor-
poration, it was found that esteriﬁed 12-HETEs are generated by incor-
poration of pre-formed 12-HETE, rather than direct oxidation of
phospholipids [29]. The rapid timescale of HETE-PL formation, which
parallels that of free 12-HETE, indicates that the enzymes needed for
this process (including PLA2, LOX and a fatty acyl CoA ligase) must be
tightly coupled, perhaps in an enzyme complex at or near the plasma
membrane of the cell. Interestingly, exogenously added 12-HETE-d8
was not incorporated into phospholipids during the short timescale of
acute platelet activation. This indicates that exogenous HETEs are not
equivalent to endogenous, further supporting the idea that generation
of endogenous free HETE is tightly coupled to its esteriﬁcation into
phospholipids.
Unlike free eicosanoids, phospholipid-esteriﬁed HETES remain cell
associated with a proportion of the HETE-PEs trafﬁcking to the outside
of the plasma membrane. It is assumed that HETE-PC is already on the
outer surface, consistent with the localization of unoxidized PC. Studies
using reductants indicate that the primary hydroperoxide lipids gener-
ated by 12-LOX are rapidly reduced endogenously by glutathione
peroxidases to their corresponding HETEs [29]. HpETE- or KETE-PLs
analogous to the monocyte/macrophage products of 12/15-LOXs were
not detected in these cells.
Platelets also generate a second family of esteriﬁed eicosanoids via
the 12-LOX pathway, where the 12-HETE is substituted by 12-LOX-
oxidized docosahexaenoic acid (DHA) [30]. The products comprise
phospholipid-esteriﬁed hydroxydocosahexaenoic acid (HDOHE),
speciﬁcally two diacyl (16:0a, 18:0a) and two plasmalogen (16:0p,
18:0p) PEs containing predominantly the 14-HDOHE positional
isomer. Studies using recombinant human 12-LOX showed the forma-
tion of predominantly free 14-HDOHE, and this, combined with its in-
ability to directly oxidize esteriﬁed DHA suggests that the formation
of HDOHE-PEs occurs via PLA2 hydrolysis of DHA, followed by 12-
LOX oxidation, then re-esteriﬁcation of free 14-HDOHE. This was
further supported by the observation that inhibition of cPLA2 blocks
their generation [30]. 14-HDOHE-PEs form acutely upon agonist acti-
vation by thrombin in a calcium dependent manner, at signiﬁcant
rates (2–4 ng/4×107 cells) [30].
4.3. Neutrophils
Neutrophils express 5-LOX which has long been known to generate
the free 5-HpETE on agonist activation by bacterial peptides, ionophore
(A23187) and phorbol esters. 5-HpETE can then be further metabolized
to 5-HETE, leukotrienes (LTB4 and cysteinyl leukotrienes) and 5-oxo-
ETE. We recently observed that that human neutrophils activated
with bacterial products (fMLP) or serum opsonized S. epidermidis
acutely generate four 5-LOX derived lipids comprising plasmalogen
and diacyl phospholipid esteriﬁed 5-HETEs (speciﬁcally 16:0a/5-
HETE-PC, 18:0p/5-HETE-PE, 18:1p/5-HETE-PE and 16:0p/5-HETE-
PE) [33]. They form in a calcium, sPLA2, cPLA2 and PLC dependent
manner via esteriﬁcation of newly generated 5-HETE and remain cell
associated, localizing to both nuclear and extra-nuclear membranes.
Their acute generation occurs within 2 min, and they are stable over a
time period of 3 h, with total 5-HETE-PEs reaching up to 0.37 ng/106
neutrophils. In contrast, the 5-HETE-PC is generated within 2 min of
activation, but rapidly metabolized to unknown products. These 5-
HETE-PEs and PC were detected in lavages from a murine model of
bacterial peritonitis, aswell as lavages frompatientswith bacterial peri-
tonitis, showing that they are formed in human disease. In murineinfection, formation of 5-HETE-PEs coincided with the neutrophil re-
cruitment to the peritoneal cavity, and their levels decreased as the
cells were cleared, suggesting neutrophil 5-LOX as their enzymatic
source. In human lavages, while 5-HETE-PEs were detected, it was not
possible to determine their source, however neutrophils are again
most likely, as levels broadly correlated with cell count [33].
4.4. Low-density lipoprotein and diseased tissue
A number of additional esteriﬁed eicosanoids have been detected
in biological samples, including low-density lipoprotein and diseased
tissue. Esteriﬁed isoprostanes and isofurans have been shown as free
acids using GC/MS, following hydrolysis of PLs [28,45–47]. In addi-
tion, intact epoxyisoprostane and epoxycyclopentenone PLs were
described using LC/MS/MS. These were puriﬁed from air oxidized PC
as a bioactive fraction, using NP-HPLC, then structurally characterized
using RP-HPLC/MS/MS [48,49]. Subsequent studies have shown that
PC-esteriﬁed epoxyisoprostane and epoxycyclopentenone can regulate
endothelial cell PPAR-α activity thereby inducing MCP-1 and IL-8
expression by these cells, both of which are involved in the recruitment
of monocytic cells to the vessel wall [50]. In support of this, other
studies have shown that 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-
glycero-3-phosphocholine can induce monocyte binding to endothelial
cells [49]. This implicates such oxidized lipids in the onset of atherogen-
esis. Epoxycyclopentenone-containing phospholipids have also been
implicated in the restoration of the endothelial barrier after acute
periods of inﬂammation or injury by mediating cytoskeletal rearrange-
ments [51]. Finally, it has been observed that host derived PC-esteriﬁed
epoxyisoprostanes accumulate in human leprosy lesions where they
are thought to inhibit innate immune responses thereby exacerbating
the pathogenesis of microbial infections [52].
5. Biological roles of esteriﬁed eicosanoids
While the roles of many oxidized phospholipids generated by
non-enzymatic pathways are quite well studied, less is known about
the roles of esteriﬁed eicosanoids generated in a speciﬁc manner by
cellular enzymes. Nonetheless, recent studies have begun to identify
speciﬁc biological actions in isolated immune cells in vitro, particularly
in the context of immune regulation and coagulation.
5.1. Regulation of coagulation
Coagulation involves the coordinated activities of plasma-derived
clotting factors (proteases), which sequentially activate leading to
formation of the prothrombinase complex (Xa/Va). This associates
with negatively charged phospholipids on the platelet plasma mem-
brane surface, where it converts prothrombin to thrombin, ultimately
leading to clot formation. Negatively charged phospholipids known to
be important in this process include PS and PE. Since HETE-PLs are
present on the outside of the platelet, we wondered what effect
they might have on coagulation. In vitro experiments using liposomes
supplemented with HETE-PCs demonstrated that these lipids could
dose-dependently enhance tissue factor-dependent coagulation in
vitro [29] (Fig. 4). PE and PS facilitate coagulation factor interactions
with the membrane via calcium binding to their negatively charged
phosphate. Although native PC is unable to mediate this interaction,
12-HETE-PCs possess a hydroxyl group at the C12 position, which
might become accessible at the cell surface as a result of fatty acid
chain bending due to the incorporation of a polar group. This may
expose the―OH group leaving it accessible to interactionwith calcium.
Alternatively, the presence of the ―OH may push the head group
further out of the membrane leading to increased accessibility of the
phosphate for calcium interactions.
Scott syndrome is a rare bleeding disorder associated with impaired
coagulation, and patients with this defect display an attenuated
prothrombin
thrombin
12-LOX
Xa/Va
FACL?
PE/PS
PC
Fig. 4. Potential role for HETE-PLs in enhancing thrombin generation. Following their
generation, some HETE-PE translocates to the outside of the plasma membrane. The
presence of ―OH groups on phospholipids results in faster rates of tissue factor-
dependent thrombin generation in vitro.
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defect in a lipid transporter protein [53]. We found that in Scott syn-
drome platelets, PS and 12-HETE-PE externalization is inhibited. How-
ever, they still generate a normal amount of HETE-PC, which may
partially explain why they are able to support a low rate of tissue
factor-dependent thrombin generation [29].
5.2. Toll-like receptor signaling inhibition
Studies on lipopolysaccharide (LPS)-stimulated human monocytes
found that 18:0a/15-HETE-PE inhibits TNF-α and G-CSF generation,
thereby acting in an anti-inﬂammatory manner [31]. Based on previous
studies on non-enzymatically-generated truncated products of PC
oxidation, we speculate that the mechanism may involve inhibition of
the interaction of LPS with either LPS-binding protein (LBP) or CD14
[54]. In this regard HETE-PE may be acting in a protective manner, to
dampen immune responses and aid in the resolution of inﬂammation
and infection (Fig. 5).
5.3. Regulation of anti-microbial actions in human neutrophils
Neutrophil extracellular traps (NETs) are weblike structures com-
prising an extracellular scaffold of DNA, which contain neutrophil anti-
microbial proteins of granular and nuclear origin. These enhance the
neutrophils ability to trap bacteria within the circulation thereby12/15-LOX
12/15-LOX
Tra
outs
ar
Ca2+
Fig. 5. HETE-PE generation and action in human monocytes. These are generated by 15-LOX
and known biological actions include regulation of LPS generation of cytokines.limiting microbial dissemination, and the associated damage from neu-
trophil granular contents [55,56]. We found that both 5- and 15-HETE-
PEs are able to inhibit neutrophil extracellular trap (NET) formation in
vitro, while inhibitors of 5-LOX enhanced their formation [33]. In
order for NETs to be generated, the nuclear membrane dissolves, and
the plasmamembrane ruptures. It is not currently known how this dis-
integration of the membranes occurs, however we can speculate that
the presence of HETE-PEs in both the nuclear and plasma membranes,
may make them well placed to potentially play a role in the release of
DNA through regulating membrane ﬂuidity or permeability.
5-HETE-PE selectively increases neutrophil generation of IL-8, but
not TNFα [33]. This is in contrast to free 5-HETE, which abolishes IL-
8 and TNFα generation by neutrophils, indicating that the free vs. es-
teriﬁed forms of these LOX products work via different mechanisms.
In contrast, both 5-HETE-PE and 5-HETE independently enhanced su-
peroxide generation in neutrophils, so in this case, the 5-HETE func-
tional group is required [33]. In terms of regulation of neutrophil
function, it is currently not clear whether 5-HETE-PEs are pro- or
anti-inﬂammatory. Increasing IL-8 and superoxide generation would
be expected to promote bacterial killing, but could also increase
host damage, while inhibition of NET generation could be either dam-
aging or beneﬁcial depending on the context (Fig. 6). Thus, further
work will be required to unravel the in vivo consequences of neutro-
phil HETE-PE generation during inﬂammatory disease or infection.
5.4. Formation of covalent adducts
A number of oxidized phospholipids and eicosanoids have been
reported to form protein adducts due to their electrophilic nature. The
presence of an α,β-unsaturated carbonyl group with the carbon chain
of such lipids affords them the ability to form both Schiff base and Mi-
chael additions with certain amino acids such as cysteine. Protein–
lipid adducts are currently of great interest and diverse biological
actions for such structures have been reported. Most of these studies
focus on free eicosanoid–protein adducts which are known to have a
number of cell signaling behaviors, however the formation of esteriﬁed
lipid–protein adducts is less well characterized. Nonetheless, studies by
one group have shown that a biotinylated form of oxidized PC readily
adducts to plasma proteins, in particular apolipoprotein A1 (ApoA1), a
core component of high-density lipoprotein (HDL) [57,58]. Other
groups have shown that isoketal containing oxidized phospholipids
formed adducts which profoundly altered protein function, inhibiting
potassium channels in a dose dependent manner [59]. Finally it has
been seen that phospholipid esteriﬁed lipid hydroperoxides may be
generated in vivo and be involved in the pathogenesis of atherosclerosis
related oxidative stress [60].nslocate to the 
ide of the cell but 
e not secreted.
Inhibit LPS induction of 
cytokines.
LPS CD14TLR4
, GCSF
through direct oxidation of the membrane, some translocate to the outside of the cell,
5-HETE-PE NETs
IL-8
Superoxide
Fig. 6. HETE-PE action in human neutrophils. 5-HETE-PE inhibits NET formation by
neutrophils but enhances IL-8 and superoxide generation. Adherent neutrophils were
activated with phorbol with (lower panel) or without (upper panel) 10 μM HETE-PE.
Histone H1: green; myeloperoxidase: red.
Part of this ﬁgure was originally published in [24].
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In animal models and human studies, increases in IL-4 and IL-13
have been shown to cause differentiation of ciliated epithelial cells
into mucus producing goblet cells resulting in mucus hypersecretion,
and contributing to severity of asthma and lung allergy. IL-4 and IL-13
induce 15-LOX, and high levels of this enzyme along with MUC5AC (a
secreted mucin, which is associated with asthma) are expressed in
human asthmatic epithelial cells [61–64]. It has been recently demon-
strated that IL-13-stimulated 15-LOX expression is associated with
generation of two species of 15-HETE-PE by human bronchial epithe-
lial cells. This generation of HETE-PEs enhanced expression of
MUC5AC, suggesting a role for esteriﬁed HETEs in contributing to
the pathophysiology of asthma [39]. Associated with these studies is
the recent ﬁnding that both 15-LOX and 15-HETE-PE can regulate
MAPK/ERK activation, which is also known to be elevated in asthma.
Speciﬁcally, 15-LOX and 15-HETE-PE induce the dissociation of
phosphatidylethanolamine-binding protein 1 (PEBP1) from Raf-1,
allowing the activation of ERK. Thus, this pathway appears to be of
central importance for enhancing critical inﬂammatory pathways in-
tegral to asthma pathogenesis [65].
5.6. Regulation of intracellular pathways by glyceryl prostaglandins
Glyceryl prostaglandins generated by the action of COX-2 in macro-
phages have distinct and in some cases, more potent biological actions
than their free acid analogs. Initial reports found that PGE2-G triggers
calcium mobilization, transient increases in inositol 1,4,5-triphosphate
(IP3), and membrane association and activation of PKC at nM concen-
trations, implicating this eicosanoid ester in the activation of a number
of signaling cascades, including the ERK/MAPK pathway [66]. More
recently, it was also found tomodulate inhibitory synaptic transmission
in mouse hippocampal neurons [67]. This is in contrast to the unoxi-
dized 2-AG, which has opposing effects at similar concentrations
(1 μM). The AEA oxidation product, PGE2-AEA inhibits LPS/IFNγ-
induced IL-12 and IL-23 expression in microglia and macrophages by
reducing expression of IL-12p40 [42]. This is similar to reported effects
of AEA itself, and pharmacological studies suggest that AEA acts follow-
ing COX-2 oxidation and formation of an EP2 receptor agonist [42].
Thus, it is clear that glyceryl-PGs play important roles in cell signaling
that are distinct to the well-described actions of their free acid analogs.
5.7. Biological actions resulting from esteriﬁcation of exogenous HETEs
and non-enzymatically-generated esteriﬁed eicosanoids
Earlier sections focused onbiological actions of endogenously gener-
ated esteriﬁed eicosanoids generated by COXs or LOXs. However, those
formed either by esteriﬁcation of exogenous HETEs or through non-enzymatic mechanisms have also been found to possess potent signal-
ing properties.
In this regard, uptake of exogenous 5-HETE into endothelial cells
inhibits histamine- and arachidonate-stimulated production of PGE2
and 6-ketoPGF1α [19]. Also, 5-HETE incorporation by adrenal
glomerulosa cells decreases aldosterone release, thereby playing a
potential role in steroidogenesis [20]. In previous studies, 12-HETE
uptake into the cellular lipids of mouse thyroid glands caused inhibi-
tion of cyclic AMP production [68]. Whether this signaling was mediat-
ed by the esteriﬁed HETE itself, or following later cleavage to regenerate
the free eicosanoid is not clear. In support, a role for esteriﬁed HETEs
acting as a pool of “stored” eicosanoid, which can be released on further
agonist activation, has been proposed (described earlier). Speciﬁcally,
fMLP, phorbol or calcium ionophore (A23187) was shown to mediate
deacylation of PI and release of 15-HETE which subsequently acts as a
second signal to inhibit LTB4 generation by the neutrophils themselves
[22].
A large number of in vivo studies have investigated the generation
and multitude of biological actions mediated by non-enzymatically
generated oxidized phospholipids in disease and signaling processes,
and for this the reader is directed to a recent comprehensive review
of this ﬁeld [69]. Many of these demonstrate functions exerted by
crude preparations of PLs that comprise a plethora of 100s of different
lipid species, likely including the families of lipids described in this
review. More recently, fractionation studies have isolated particular
bioactive species from these mixtures and many highlight in particu-
lar the potent signaling actions of lipids formed through truncation of
the oxidized arachidonate at sn2. These would not be considered
eicosanoids however since the C20 hydrocarbon chain is no longer in-
tact. Of relevance, lysoPC-containing 15-hydroxyeicosapentaenoyl
(1-(15-hydroxyeicosapentaenoyl)-lysoPC (15-HEPE-lysoPC)) has been
shown to play a number of anti-inﬂammatory roles in a murine model
of peritonitis. Speciﬁcally, i.p. administration of this lipid inhibited plas-
ma leakage, and decreased leukocyte inﬁltration. In addition, it reduced
formation of the 5-LOXproducts, LTC4 and LTB4, aswell as levels of pro-
inﬂammatory cytokines. Additionally, 15-HEPE-lysoPC caused a partial
suppression of LTC4-induced plasma leakage and LTB4-induced leuko-
cyte inﬁltration [70]. A number of other studies have shown that Ox-
PAPC and PS are ligands for CD36 expressed by macrophages, and
their binding enhances foam cell formation, and uptake of apoptotic
cells, both key elements in the pathology of atherosclerosis [71–73].
As before, most of these activities appear to be mediated primarily by
truncated products rather than esteriﬁed intact eicosanoids.
6. Conclusion
Eicosanoids were traditionally considered to signal as free acid me-
diators via speciﬁc G protein-coupled receptors, following their genera-
tion and secretion from cells. More recently, a new paradigm has
emerged whereby they are generated by primary immune cells on
acute activation. This suggests that esteriﬁed eicosanoids are families
of signaling intermediates in their own right, mediating distinct and
sometimesmore potent biological actions to their un-esteriﬁed analogs.
The recent advances in high sensitivity bench top mass spectrometry
instrumentation have also been a signiﬁcant factor in enabling this
research, allowing detailed characterization of molecular structure
(e.g. sn1 fatty acids, as well as head group) of novel lipid families for
the ﬁrst time. Current efforts in this area are focused on increasing our
understanding of the detailed biological actions of these lipids in vivo,
and delineating their role in disease processes.
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